45 results
8-K
EX-99.1
MLTX
MoonLake Immunotherapeutics - Ordinary Shares
7 May 24
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
8:01am
Questionnaire-Disability Index, enthesitis as measured by the Leeds Enthesitis Index and pain as measured by the Patients Assessment of Arthritis Pain. Further
8-K
EX-99.2
MLTX
MoonLake Immunotherapeutics - Ordinary Shares
11 Mar 24
Regulation FD Disclosure
8:01am
; HAQ - DI, Health Assessment Questionnaire Disability Index; PASI, Psoriasis Area and Severity Index; PRO, patient - reported outcome; S/TJC, swollen … of lost work and nearly 3x disability days vs controls 4 18 8 11 8 4 4 0 5 10 15 20 Observed annual rate Patients with HS Control groups Total days
8-K
EX-99.1
sv91ez1dfvt pwsu1
11 Mar 24
Regulation FD Disclosure
8:01am
8-K
EX-99.1
enqbcjobq578vs
29 Feb 24
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
8:03am
8-K
EX-99.1
bq75dgnpg0l 5wmxlgw4
14 Nov 23
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
12:00am
8-K
EX-99.2
fcgdr0j
6 Nov 23
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
7:55am
8-K
EX-99.1
6186o
6 Nov 23
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
7:55am
8-K
EX-99.1
hq8q2tna0n013iyu5nmb
10 Aug 23
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
8:15am
DEF 14A
jqpd9zxs
26 Apr 23
Definitive proxy
4:31pm
424B3
rgtcs 79j5
14 Nov 22
Prospectus supplement
8:32am